Geller Advisors’s Acceleron Pharma XLRN Stock Holding History

Geller Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-18,750	Closed	-$994K	–	82
2019 Q4	$994K	Hold	18,750	–	–	0.31%	16
2019 Q3	$741K	Hold	18,750	–	–	0.27%	17
2019 Q2	$770K	Hold	18,750	–	–	0.3%	12
2019 Q1	$873K	Hold	18,750	–	–	0.35%	12
2018 Q4	$817K	Hold	18,750	–	–	0.38%	13
2018 Q3	$1.07M	Hold	18,750	–	–	0.63%	9
2018 Q2	$910K	Hold	18,750	–	–	0.4%	13
2018 Q1	$733K	Buy	+18,750	New	+$797K	0.36%	13

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Geller Advisors's XLRN Position: Q1 2020 in Review

Geller Advisors sold out of Acceleron Pharma (XLRN) in Q1 2020, closing a stake of 18,750 shares — an estimated $994K sold.

Geller Advisors first reported a position in XLRN in Q1 2018 and held it in 8 quarters. The position peaked at $1.07M in Q3 2018. 217 funds tracked by Wall St. Rank hold XLRN as of Q1 2020.

Geller Advisors reported no remaining Acceleron Pharma position as of Q1 2020 after selling out during the quarter.
Geller Advisors sold 18,750 Acceleron Pharma shares in Q1 2020, an estimated $994K.
Geller Advisors first reported a position in Acceleron Pharma in Q1 2018 and held it in 8 quarters.
Geller Advisors's Acceleron Pharma position peaked at $1.07M in Q3 2018.
217 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2020.

Based on Geller Advisors's 13F filing for Q1 2020, filed 12 May 2020.